These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Viral-associated trichodysplasia of immunosuppression in a renal transplant patient. Blake BP; Marathe KS; Mohr MR; Jones N; Novosel T J Drugs Dermatol; 2011 Apr; 10(4):422-4. PubMed ID: 21455555 [No Abstract] [Full Text] [Related]
7. Facial Papules in Frontal Fibrosing Alopecia: Good Response to Isotretinoin. Flores-Terry MÁ; García-Arpa M; Franco-Muñóz M; González-Ruiz L Actas Dermosifiliogr (Engl Ed); 2018 Nov; 109(9):831-833. PubMed ID: 29395031 [No Abstract] [Full Text] [Related]
8. A safety study of oral valganciclovir maintenance treatment of cytomegalovirus retinitis. Lalezari J; Lindley J; Walmsley S; Kuppermann B; Fisher M; Friedberg D; Lalonde R; Matheron S; Nieto L; Torriani FJ; Van Syoc R; Sutton MA; Buhles W; Stempien MJ; J Acquir Immune Defic Syndr; 2002 Aug; 30(4):392-400. PubMed ID: 12138345 [TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of valganciclovir and ganciclovir following multiple oral dosages of valganciclovir in HIV- and CMV-seropositive volunteers. Brown F; Banken L; Saywell K; Arum I Clin Pharmacokinet; 1999 Aug; 37(2):167-76. PubMed ID: 10496303 [TBL] [Abstract][Full Text] [Related]
10. Oral valganciclovir as pre-emptive therapy has similar efficacy on cytomegalovirus DNA load reduction as intravenous ganciclovir in allogeneic stem cell transplantation recipients. van der Heiden PL; Kalpoe JS; Barge RM; Willemze R; Kroes AC; Schippers EF Bone Marrow Transplant; 2006 Apr; 37(7):693-8. PubMed ID: 16501590 [TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of ganciclovir after oral valganciclovir versus intravenous ganciclovir in allogeneic stem cell transplant patients with graft-versus-host disease of the gastrointestinal tract. Winston DJ; Baden LR; Gabriel DA; Emmanouilides C; Shaw LM; Lange WR; Ratanatharathorn V Biol Blood Marrow Transplant; 2006 Jun; 12(6):635-40. PubMed ID: 16737936 [TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of valganciclovir and ganciclovir in renal impairment. Czock D; Scholle C; Rasche FM; Schaarschmidt D; Keller F Clin Pharmacol Ther; 2002 Aug; 72(2):142-50. PubMed ID: 12189361 [TBL] [Abstract][Full Text] [Related]
13. Similar reduction of cytomegalovirus DNA load by oral valganciclovir and intravenous ganciclovir on pre-emptive therapy after renal and renal-pancreas transplantation. Kalpoe JS; Schippers EF; Eling Y; Sijpkens YW; de Fijter JW; Kroes AC Antivir Ther; 2005; 10(1):119-23. PubMed ID: 15751769 [TBL] [Abstract][Full Text] [Related]
14. Valganciclovir. Curran M; Noble S Drugs; 2001; 61(8):1145-50 ; discussion 1151-2. PubMed ID: 11465875 [TBL] [Abstract][Full Text] [Related]
15. Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients. Wiltshire H; Paya CV; Pescovitz MD; Humar A; Dominguez E; Washburn K; Blumberg E; Alexander B; Freeman R; Heaton N; Zuideveld KP; Transplantation; 2005 Jun; 79(11):1477-83. PubMed ID: 15940035 [TBL] [Abstract][Full Text] [Related]
16. The efficacy and safety of valganciclovir vs. oral ganciclovir in the prevention of symptomatic CMV infection in children after solid organ transplantation. Lapidus-Krol E; Shapiro R; Amir J; Davidovits M; Steinberg R; Mor E; Avitzur Y Pediatr Transplant; 2010 Sep; 14(6):753-60. PubMed ID: 20477976 [TBL] [Abstract][Full Text] [Related]